Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilpivirine Pediatric Formulations Bioavailability and Food Effect
NCT02561936Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rilpivirine in human immunodeficiency virus type 1 infection (HIV-1) (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time and 1 more. Started Oct 2015; status: completed.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02561936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561936.